BSECompany Update1d ago · 24 Sept 2026, 12:43 pm
Please find attached herewith intimation for change in Key Managerial Personnel - Resignation of Chief Financial Officer
Alkem Laboratories Ltd · 539523
✦ AI SummaryMgmt Change
Alkem Laboratories Ltd announced the resignation of Mr. Nitin Agrawal as Chief Financial Officer, effective September 30, 2026, to pursue new professional opportunities.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Cessation
Attachments (1)
📄pdf
Download →
4d4b7168-ae8a-4352-9352-a0d9b79bbe07.pdf
View document text
24th September, 2026
The Corporate Relationship National Stock Exchange of India
Department Limited
BSE Limited Exchange Plaza,
Phiroze Jeejeebhoy Towers, Bandra Kurla Complex,
Dalal Street, Bandra East,
Mumbai 400 001. Mumbai 400 051.
Scrip Code: 539523 Scrip Symbol: ALKEM
Sub: Disclosure under Regulation 30(2) of Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (“SEBI
LODR Regulations”): Change in Key Managerial Personnel – Resignation of Chief
Financial Officer
Dear Sir(s)/Madam,
Pursuant to Regulation 30 of SEBI LODR Regulations, we wish to inform you that
Mr. Nitin Agrawal has resigned on 30th July, 2026 from the position of Chief Financial Officer
& Key Managerial Personnel of the Company to pursue new professional opportunities.
Accordingly, Mr. Nitin Agrawal shall cease to hold Senior Management Position of the
Company effective from 30th September, 2026.
Further, the details as required in terms of Regulation 30 read with Schedule III of the SEBI
LODR Regulations and SEBI Master Circular bearing No. HO/49/14/14(7)2025-
CFDPOD2/I/3762/2026 dated January 30, 2026 is provided in Annexure I to this letter and a
copy of resignation letter dated 30th July, 2026 tendered by Mr. Nitin Agrawal as the Chief
Financial Officer (CFO) is enclosed herewith as Annexure II.
The above information is also available on the website of the Company at
www.alkemlabs.com.
Kindly take the same on your records.
Sincerely,
For Alkem Laboratories Limited
Manish Narang
President – Legal, Company Secretary & Compliance Officer
Encl: a/a
Annexure I
(Disclosure in terms of Regulation 30 of the SEBI LODR Regulations read with SEBI Master
Circular bearing Ref.No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30,
2026)
Sr. No. Particulars Details
1. Reason for change viz. Resignation
appointment, re-appointment,
resignation, removal, death or
otherwise
2. Date of appointment/ re- Mr. Nitin Agrawal shall cease to be Senior
appointment/ cessation (as Management Personnel, effective from 30th
applicable) and term of September, 2026
appointment/ reappointment
3. Brief Profile Not Applicable
4. Disclosure of relationships Not Applicable
between directors
Annexure II